Drug discovery is undergoing a transformation across many fronts from the implementation of generative AI approaches, to the growing resurgence in omics-based solutions, to the emergence of novel therapeutic modalities. What remains constant however is the fundamental need to deliver high-quality, impactful data in less time using less resources. The historical paradigm of either focusing on either speed or depth of data has resulted in a myriad of assays that excel in one of these areas but under-deliver in the other. Real-time, label-free binding using biosensors is no exception and has long been a technology space that while rich in data outputs could never match the throughput requirements of robust research workflows.
HT-SPR however, is re-writing the way real-time, label-free binding assays are deployed in modern research strategies. With the ability to screen samples across the spectrum of small molecules to mAbs and approaching 150,000 detailed binding interactions in a single experiment, the Carterra LSAXT operates at an unmatched scale for binding characterization. Importantly, these capabilities come with less resource requirements than any other approach owing to the novel microfluidics of the LSAXT. This talk will highlight the unique advantages of HT-SPR for highly scaled, real-time, label-free binding with examples across multiple sample types and most importantly how these measurements drive the intelligent selection of drug candidates.